UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort

Journal of antimicrobial chemotherapy, 2010-07, Vol.65 (7), p.1466-1471

2010

Volltextzugriff (PDF)

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome

Leukemia, 2013-01, Vol.27 (1), p.82-91

2013

Volltextzugriff (PDF)

Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy—evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO)

Annals of oncology, 2014-09, Vol.25 (9), p.1709-1718

2014

Volltextzugriff (PDF)

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

Leukemia, 2012-06, Vol.26 (6), p.1286-1292

2012

Volltextzugriff (PDF)

Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia

Leukemia, 2017-10, Vol.31 (10), p.2271-2273

2017

Volltextzugriff (PDF)

Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome

European journal of clinical pharmacology, 2012-06, Vol.68 (6), p.987-995

2012

Volltextzugriff (PDF)

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

The New England journal of medicine, 2019-06, Vol.380 (23), p.2225-2236

2019

Volltextzugriff (PDF)

Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab

Leukemia, 2016-08, Vol.30 (8), p.1763-1766

2016

Volltextzugriff (PDF)

Wnt/β-catenin/LEF-1 signaling in chronic lymphocytic leukemia (CLL): a target for current and potential therapeutic options

Current cancer drug targets, 2010-11, Vol.10 (7), p.716-727

2010

Volltextzugriff (PDF)

S148: VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5‐YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY

HemaSphere, 2022-06, Vol.6, p.49-50

2022

Volltextzugriff (PDF)

S143: TRANSCRIPTOMIC CHARACTERIZATION OF MRD RESPONSE AND NON‐RESPONSE IN PATIENTS TREATED WITH FIXED‐DURATION VENETOCLAX‐OBINUTUZUMAB

HemaSphere, 2022-06, Vol.6, p.44-45

2022

Volltextzugriff (PDF)

Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique

Annals of hematology, 2003-05, Vol.82 (5), p.284-289

2003

Volltextzugriff (PDF)

LightCycler technology for the quantitation of bcr/abl fusion transcripts

Cancer research (Chicago, Ill.), 1999-07, Vol.59 (13), p.3171-3174

1999

Volltextzugriff (PDF)

Highly sensitive and specific fluorescence reverse transcription-PCR assay for the pseudogene-free detection of β-actin transcripts as quantitative reference

Clinical chemistry (Baltimore, Md.), 1999-02, Vol.45 (2), p.297-300

1999

Volltextzugriff (PDF)

Quantitative analysis of beta-actin, beta-2-microglobulin and porphobilinogen deaminase mRNA and their comparison as control transcripts for RT-PCR

Molecular and cellular probes, 2002-02, Vol.16 (1), p.25-30

2002

Volltextzugriff (PDF)

Serum selenium, plasma glutathione (GSH) and erythrocyte glutathione peroxidase (GSH-Px)-levels in asymptomatic versus symptomatic human immunodeficiency virus-1 (HIV-1)-infection

European journal of clinical nutrition, 1997-04, Vol.51 (4), p.266-272

1997

Volltextzugriff (PDF)

Pathogenesis and pathophysiology of anemia in HIV infection

Annals of hematology, 1997-11, Vol.75 (5-6), p.179-187

1997

Volltextzugriff (PDF)

GENETIC MARKERS AND OUTCOME WITH FRONT LINE OBINUTUZUMAB PLUS EITHER CHLORAMBUCIL OR VENETOCLAX ‐ UPDATED ANALYSIS OF THE CLL14 TRIAL

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

VENETOCLAX‐OBINUTUZUMAB MODULATES CLONAL GROWTH: RESULTS OF A POPULATION‐BASED MINIMAL RESIDUAL DISEASE MODEL FROM THE RANDOMIZED CLL14 STUDY

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

BENDAMUSTINE, FOLLOWED BY OBINUTUZUMAB, ACALABRUTINIB AND VENETOCLAX IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2‐BAAG TRIAL OF THE GCLLSG

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

Patients with haematological malignancies show a restricted body image focusing on function and emotion

European journal of cancer care, 2005-05, Vol.14 (2), p.155-165

2005

Volltextzugriff (PDF)

Leukämien: Fortschritt in der Diagnostik im Kontext der minimalen Resterkrankung

Forum (Heidelberg), 2020-09, Vol.35 (4), p.352-354

Kreuzer, K.-A.

2020

Volltextzugriff (PDF)

THE CLL‐RT1 TRIAL: A MULTICENTER PHASE‐2 TRIAL OF ZANUBRUTINIB, A BTK INHIBITOR, PLUS TISLELIZUMAB, A PD‐1 INHIBITOR, FOR PATIENTS WITH RICHTER TRANSFORMATION

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4‐YEAR FOLLOW‐UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

1 – 25 von 229

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(204)
Mit Volltextzugriff
(113)

Publikationsform

Sprache

Englisch
(218)
Deutsch
(9)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies

Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome

Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy—evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO)

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia

Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab

Wnt/β-catenin/LEF-1 signaling in chronic lymphocytic leukemia (CLL): a target for current and potential therapeutic options

S148: VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5‐YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY

S143: TRANSCRIPTOMIC CHARACTERIZATION OF MRD RESPONSE AND NON‐RESPONSE IN PATIENTS TREATED WITH FIXED‐DURATION VENETOCLAX‐OBINUTUZUMAB

Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique

LightCycler technology for the quantitation of bcr/abl fusion transcripts

Highly sensitive and specific fluorescence reverse transcription-PCR assay for the pseudogene-free detection of β-actin transcripts as quantitative reference

Quantitative analysis of beta-actin, beta-2-microglobulin and porphobilinogen deaminase mRNA and their comparison as control transcripts for RT-PCR

Serum selenium, plasma glutathione (GSH) and erythrocyte glutathione peroxidase (GSH-Px)-levels in asymptomatic versus symptomatic human immunodeficiency virus-1 (HIV-1)-infection

Pathogenesis and pathophysiology of anemia in HIV infection

GENETIC MARKERS AND OUTCOME WITH FRONT LINE OBINUTUZUMAB PLUS EITHER CHLORAMBUCIL OR VENETOCLAX ‐ UPDATED ANALYSIS OF THE CLL14 TRIAL

VENETOCLAX‐OBINUTUZUMAB MODULATES CLONAL GROWTH: RESULTS OF A POPULATION‐BASED MINIMAL RESIDUAL DISEASE MODEL FROM THE RANDOMIZED CLL14 STUDY

BENDAMUSTINE, FOLLOWED BY OBINUTUZUMAB, ACALABRUTINIB AND VENETOCLAX IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2‐BAAG TRIAL OF THE GCLLSG

Patients with haematological malignancies show a restricted body image focusing on function and emotion

Leukämien: Fortschritt in der Diagnostik im Kontext der minimalen Resterkrankung

THE CLL‐RT1 TRIAL: A MULTICENTER PHASE‐2 TRIAL OF ZANUBRUTINIB, A BTK INHIBITOR, PLUS TISLELIZUMAB, A PD‐1 INHIBITOR, FOR PATIENTS WITH RICHTER TRANSFORMATION

VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4‐YEAR FOLLOW‐UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY

Suchergebnisse filtern